Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether genetic modification of calcium handling through deletion of phospholamban in mice would affect the development of heart failure in mice with transgenic overexpression of the beta1-adrenergic receptor.
|
14967726 |
2004 |
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We envision a self-reinforcing mechanism beginning with phosphomimetic R9C-PLB oxidation and loss of SERCA inhibition, leading to impaired calcium regulation and heart failure.
|
25593317 |
2015 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Transgenic PLN(R9C) mice recapitulated human heart failure with premature death.
|
12610310 |
2003 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Transgenic PLN(R9C) mice recapitulated human heart failure with premature death.
|
12610310 |
2003 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
To clarify whether pVHL is involved in PLN degradation in failing hearts, we used carbonylcyanide <i>m</i>-chlorophenylhydrazone (CCCP), a mitochondrial membrane potential (MMP)-lowering reagent, to mimic the heart failure condition in PLN-expressing HEK293 cells and found that CCCP treatment resulted in PLN degradation and increased interaction between PLN and pVHL.
|
29068413 |
2017 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Through genetic screening of dilated cardiomyopathy patients, we identified a previously uncharacterized deletion of arginine 14 (PLN-R14Del) in the coding region of the phospholamban (PLN) gene in a large family with hereditary heart failure.
|
16432188 |
2006 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These results support the development of the PLN repressor as therapy for heart failure, and provide evidence that delivery of engineered ZFP TFs to native organs can drive therapeutically relevant levels of gene repression in vivo.
|
22828502 |
2012 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results suggest that PLN deletion would be a promising approach to improve both mortality and cardiac function in the heart failure.
|
27992596 |
2016 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These results show that LOF PLB(M) can compete both physically and functionally with PLB(W), provide a rational explanation for the partial success of S16E-based gene therapy in animal models of heart failure, and establish a powerful platform for designing and testing more effective PLB(M) targeted for gene therapy of heart failure in humans.
|
21510919 |
2011 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
These results establish this FRET assay as a rapid and quantitative means of screening PLB(M) for optimization of gene therapy to activate SERCA, as needed for gene therapy in HF.
|
22405774 |
2012 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the human G147D PPI-1 can attenuate responses of cardiomyocytes to beta-adrenergic agonists by decreasing PLN phosphorylation and therefore may contribute to deteriorated function in heart failure.
|
18192322 |
2008 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the g.203A>C genetic variant in the human PLN promoter may contribute to depressed contractility and accelerate functional deterioration in heart failure.
|
18241046 |
2008 |
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These data also show that the altered SR function in human heart failure cannot be explained by altered protein levels of PLB and SERCA2.
|
8689655 |
1996 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
The potential physiological relevance of PLB function in human heart failure is also covered.
|
9790566 |
1998 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
The data demonstrate an association between the dose-dependent inhibition of SERCA2a activity by PLN(wt) and the time of onset of heart failure and show that a weak inhibitor of SERCA2a, PLN(R9C), which is diminished in its ability to modify the level of SERCA2a activity, leads to heart failure despite fast sarcoplasmic reticulum Ca(2+) reuptake.
|
19139388 |
2009 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
The ablation of a muscle-specific sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) inhibitor, phospholamban, rescued the spectrum of phenotypes that resemble human heart failure.
|
10555147 |
1999 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The p.Arg14del founder mutation in the gene encoding phospholamban (PLN) is associated with an increased risk of malignant ventricular arrhythmia (VA) and heart failure.
|
29635323 |
2019 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Targeting phospholamban by gene transfer in human heart failure.
|
11864915 |
2002 |
Heart failure
|
0.300 |
Therapeutic
|
disease |
RGD |
Rosuvastatin was found to ameliorate the heart failure in aged SHRs and to improve changes in SERCA-2a, PLB, RyR2, NCX1, CaMKII and PPI-1; PKCα/β2 signal pathway to be suppressed; the protective effect of Rosuvastatin to be dose dependent.
|
22970977 |
2012 |
Heart failure
|
0.300 |
Therapeutic
|
disease |
RGD |
Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction.
|
22947202 |
2012 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Pathogenic variants in human phospholamban coding gene (PLN) are known to cause hereditary dilated cardiomyopathy with heart failure in an autosomal dominant mode.
|
30638982 |
2019 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
One compound increases SERCA2a calcium affinity in cardiac membranes but not in skeletal, suggesting that the compound is acting specifically on the SERCA2a-PLB complex, as needed for a drug to mitigate deficient calcium transport in heart failure.
|
30135432 |
2018 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the gene encoding PLN have been associated with idiopathic dilated cardiomyopathy; however, no systematic search for PLN mutations in heart failure has been conducted.
|
22137083 |
2011 |
Heart failure
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the phospholamban (PLN) gene are associated with dilated cardiomyopathy (DCM) and severe heart failure.
|
26917049 |
2016 |
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mutations and post-translational modifications of PLN may lead to dilated cardiomyopathy (DCM) and heart failure.
|
29501609 |
2018 |